ReviewJournal of personalized medicine2026
The Gut-Skin Axis in Atopic Dermatitis and Inflammatory Bowel Disease: Mechanisms, Microbiota, and Therapeutic Implications.
Review in Journal of personalized medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut-skin axis is a bidirectional communication network linking the gastrointestinal tract, skin, microbiota, and immune system. As major barrier organs, the gut and skin harbor complex microbial communities that contribute to tissue homeostasis, immune regulation, and protection from environmental insults. Increasing evidence indicates that dysbiosis of the gut and skin microbiota is associated with inflammatory diseases through interconnected microbial, metabolic, and immune pathways. Clinical observations further reveal strong associations between gastrointestinal disorders, including inflammatory bowel disease (IBD) and celiac disease, and cutaneous manifestations. Atopic dermatitis (AD) is characterized by epithelial barrier dysfunction, immune dysregulation, microbial imbalance, and environmental influences. Patients with AD frequently exhibit reduced gut microbial diversity, depletion of beneficial short-chain fatty acid (SCFA)-producing bacteria, and enrichment of potentially pathogenic microorganisms. Cutaneous dysbiosis, particularly expansion of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.